Faculdade de Medicina Do ABC, Post-Graduation Program, Full Researcher, Santo André, Rua Carneiro Leão 33, Vila Scarpelli, Santo André, São Paulo, Brazil.
Santa Casa de Misericórida de Porto Alegre, Porto Alegre, RS, Brazil.
Inflamm Res. 2023 Jun;72(6):1257-1274. doi: 10.1007/s00011-023-01744-w. Epub 2023 May 22.
The discovery of new inflammatory pathways and the mechanism of action of inflammatory, autoimmune, genetic, and neoplastic diseases led to the development of immunologically driven drugs. We aimed to perform a narrative review regarding the rising of a new class of drugs capable of blocking important and specific intracellular signals in the maintenance of these pathologies: the small molecules.
MATERIALS/METHODS: A total of 114 scientific papers were enrolled in this narrative review.
We describe in detail the families of protein kinases-Janus Kinase (JAK), Src kinase, Syk tyrosine kinase, Mitogen-Activated Protein Kinase (MAPK), and Bruton Tyrosine Kinase (BTK)-their physiologic function and new drugs that block these pathways of intracellular signaling. We also detail the involved cytokines and the main metabolic and clinical implications of these new medications in the field of dermatology.
Despite having lower specificity compared to specific immunobiological therapies, these new drugs are effective in a wide variety of dermatological diseases, especially diseases that had few therapeutic options, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo.
新的炎症途径的发现以及炎症、自身免疫、遗传和肿瘤疾病的作用机制导致了免疫驱动药物的发展。我们旨在对一类新的药物进行叙述性综述，这些药物能够阻断这些疾病中维持这些病理的重要和特定的细胞内信号：小分子。
材料/方法：共纳入 114 篇科学论文进行了叙述性综述。
我们详细描述了蛋白激酶家族——Janus 激酶（JAK）、Src 激酶、Syk 酪氨酸激酶、丝裂原活化蛋白激酶（MAPK）和布鲁顿酪氨酸激酶（BTK）——它们的生理功能以及阻断这些细胞内信号转导途径的新药。我们还详细描述了涉及的细胞因子以及这些新药在皮肤科领域的主要代谢和临床意义。
尽管与特异性免疫生物疗法相比特异性较低，但这些新药在多种皮肤科疾病中都有疗效，尤其是那些治疗选择较少的疾病，如银屑病、银屑病关节炎、特应性皮炎、斑秃和白癜风。
